Efficacy of low-dose @entity9940 on lower urinary tract symptoms suggestive of XXXX : a nonblind multicentre korean study.

@entity1 @entity1067 @entity9940
OBJECTIVE: To evaluate the efficacy and tolerability of @entity9940 0.2mg once daily in Korean @entity1 with lower urinary tract symptoms (LUTS) suggestive of @entity1067 ( @entity1067 ), who were treated for up to 1 year. MATERIALS AND METHODS: Of the 211 @entity1 from six urology outpatient centres who participated in this investigation, 146 @entity1 were evaluable. @entity9940 0.2 mg/day was administered orally in a nonblind design for a 1-year period. The primary efficacy parameters were improvement in the total, obstructive and irritative International Prostate Symptom Score (IPSS), measured at baseline and at weeks 12, 24, 36 and 52, and in the maximal urinary flow rate (Qmax) measured at baseline and at weeks 24 and 52. The secondary efficacy parameters were a decrease of >/=30% in IPSS, and an increase in Qmax of >/=30% from baseline. Changes in parameters between baseline and 52 weeks were assessed using Student's paired t-test. RESULTS: Statistically significant, gradual improvements in all efficacy parameters were observed over the 1-year period. @entity9940 0.2 mg/day resulted in a mean reduction of 41.1% in total IPSS (p < 0.001) and a mean increase of 4.56 mL/sec in Qmax at 52 weeks (p < 0.001). @entity9940 was well tolerated; adverse events occurred in 6.2% of @entity1 and there were no withdrawals as a result of adverse events. There were no significant changes in blood pressure or pulse rate during the study. CONCLUSIONS: One-year treatment with @entity9940 0.2 mg/day in Korean @entity1 with suspected @entity1067 was well tolerated and effective in improving LUTS and urinary flow. The effect on symptoms was apparent after 12 weeks of treatment, and symptom improvement was observed for up to 1 year.
